ERBB2 and neoplasm: CAdTrio intratumoral administration enhanced HER2.CART migration to the primary tumor site and stimulated the systemic immune response which led to both primary tumor eradication and metastatic disease control, providing new combination options to tackle pancreatic cancer (91) (Figures 2B, E).